Search research articles
Contact Us
Filters
Showing results (241-250 of 339) with videos related to
Page
of 34
Sort By:
Blood Cancer Journal
|
April 7, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Amer M Zeidan, Valeria Santini, María Díez-Campelo, et al.
Annals of Hematology
|
April 5, 2017
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Friederike Braulke, Xenia Schulz, Ulrich Germing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities
Stefan Gröschel, Sanne Lugthart, Richard F Schlenk, et al.
Leukemia Research
|
October 3, 2015
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
Fabian Beier, Behzad Kharabi Masouleh, Guntram Buesche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2020
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P Steensma, Pierre Fenaux, Koen Van Eygen, et al.
Annals of Hematology
|
January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes
Peter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 16, 2007
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
Manuel Aivado, Dimitrios Spentzos, Ulrich Germing, et al.
Leukemia
|
January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat
Valeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Blood Cancer Journal
|
December 31, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
Rami S Komrokji, Valeria Santini, Amer M Zeidan, et al.
Nature Medicine
|
October 24, 2024
Author Correction: Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Rebekka K Schneider, Monica Schenone, Monica Ventura Ferreira, et al.
Page
of 34
Search research articles
Search
Showing results (241-250 of 339) with videos related to
Sort By:
Page
of 34
Blood Cancer Journal
|
April 7, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Amer M Zeidan, Valeria Santini, María Díez-Campelo, et al.
Annals of Hematology
|
April 5, 2017
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Friederike Braulke, Xenia Schulz, Ulrich Germing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities
Stefan Gröschel, Sanne Lugthart, Richard F Schlenk, et al.
Leukemia Research
|
October 3, 2015
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
Fabian Beier, Behzad Kharabi Masouleh, Guntram Buesche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2020
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P Steensma, Pierre Fenaux, Koen Van Eygen, et al.
Annals of Hematology
|
January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes
Peter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 16, 2007
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
Manuel Aivado, Dimitrios Spentzos, Ulrich Germing, et al.
Leukemia
|
January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat
Valeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Blood Cancer Journal
|
December 31, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
Rami S Komrokji, Valeria Santini, Amer M Zeidan, et al.
Nature Medicine
|
October 24, 2024
Author Correction: Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Rebekka K Schneider, Monica Schenone, Monica Ventura Ferreira, et al.
Page
of 34